A randomized, double-blind, parallel controlled phase I clinical trial to determine the equivalence of pharmacokinetics and safety, immunogenicity and tolerability between HS016 and China-licensed adalimumab in healthy male subjects
Latest Information Update: 03 Feb 2020
At a glance
- Drugs Adalimumab (Primary) ; Adalimumab (Primary)
- Indications Ankylosing spondylitis; Plaque psoriasis; Rheumatoid arthritis
- Focus Pharmacokinetics
Most Recent Events
- 03 Feb 2020 New trial record